

RECEIVED
CENTRAL FAX CENTER

NOV 29 2005

PATENT
674583-2001AMENDMENT

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

IN THE CLAIMS:

Kindly amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, to read as follows:

1. (Currently Amended) A first composition comprising consisting essentially of an isolated coagulation factor IXa and a second composition comprising consisting essentially of an isolated coagulation factor VIII, for simultaneous, simultaneous separate or sequential use in the treatment of haemophilia A or haemophilia B in a subject who does not present with anti-coagulation factor VIII anti-FVIII antibodies.
2. (Currently Amended) A method of making a composition according to claim 18 comprising of using a isolated coagulation factor IXa and a isolated coagulation factor VIII in the preparation of a composition according to claim 1 for the treatment of haemophilia A or haemophilia B in a subject which does not present with anti- coagulation factor VIII antibodies wherein the method comprises admixing coagulation factors IXa and VIII.
3. (Currently Amended) A composition comprising consisting essentially of an isolated coagulation factor IXa FIXa according to claim 1, which further comprises phospholipid.
4. (Currently Amended) A method of using FIXa in the manufacture of a composition comprising FVIII for the treatment of treating haemophilia A or haemophilia B, comprising administering to a subject in need thereof a composition consisting essentially of coagulation factors VIII and IXa, wherein the presence of coagulation factor IXa FIXa allows the concentration of coagulation factor VIII FVIII in the composition to be reduced in comparison to a composition which does not comprise a coagulation factor IXa FIXa.

PATENT
674583-2001

5. (Currently Amended) The method according to claim 4, wherein the composition is administered to a subject who does not present with anti-coagulation factor VIII anti-FVIII antibodies.
6. (Currently Amended) The method according to claim 4, wherein the coagulation factor: VIII and IXa FVIII and FIXa reagents are produced using recombinant DNA technology.
7. (Original) The method according to claim 4, wherein the composition further comprises phospholipid.
8. (Currently Amended) The method according to claim 4, wherein the composition is formulated to provide coagulation factor VIII FVIII to a subject at a dosage of between 2 and 10 IU/kg.
9. (Withdrawn) A method for treating a subject suffering from haemophilia A or haemophilia B, comprising administering to a subject in need thereof a composition comprising FIXa and FVIII, wherein said subject does not present with anti-FVIII antibodies or wherein said composition comprises FVIII in an amount lower than that required for treatment of said subject with a composition lacking FIXa.
10. (Withdrawn) The method according to claim 9, wherein said composition further comprises phospholipid.
11. (Withdrawn) The method according to claim 9, wherein the composition comprises recombinant FIXa and recombinant FVIII.
12. (Withdrawn) The method according to claim 9, wherein the composition is formulated to provide FVIII to a subject at a dosage of between 2 and 10 IU/kg.

PATENT
674583-2001

13. (Currently Amended) A method for potentiating coagulation VIII FVIII comprising the step of mixing together coagulation factors VIII and IXa Factor FVIII and FIXa into a composition.

14. (Original) The method according to claim 13, wherein said composition further comprises phospholipid.

15. (Currently Amended) The method according to claim 13, wherein the composition comprises recombinant coagulation factor IXa FIXa and recombinant coagulation factor VIII FVIII.

16. (Withdrawn) A method for reducing the immunogenicity of FVIII in a composition comprising FVIII in a subject, comprising administering FVIII together with FIXa to the subject.

17. (Withdrawn) A method of using FIXa and FVIII in the preparation of a composition for the treatment of haemophilia, wherein the FVIII in said composition has reduced immunogenicity as a result of the presence of FIXa.

18. (New) A composition comprising the first composition according to claim 1 and the second composition according to claim 1.